Biotech News

Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR Symposium in Barcelona

Aprea Therapeutics (APRE)Aprea TherapeuticsClinical readout

Safety profile to date with continuous daily dosing supports continued dose optimization and clinical development Pharmacodynamic data demonstrate WEE1 target engagement across multiple doses, pharmacokinetics support once-daily administration Planned expansion into focused cohorts in uterine

Related news

APREAprea Therapeutics2026-11-04 13:30 EST

Aprea Therapeutics Announces Third Quarter 2026 Financial Results

MGNXMacroGenics2026-10-15 20:05 EST

MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors

APREAprea Therapeutics2026-10-16 12:30 EST

Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology

NRIXNurix Therapeutics2026-11-05 12:00 EST

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

BMYBMYBristol-Myers Squibb Company2026-10-12 10:55 EST

Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs

MGNXMacroGenics2026-10-26 11:06 EST

MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer

JNJJohnson & Johnson2026-10-25 14:24 EST

Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer

CMPXCompass Therapeutics2026-10-24 08:15 EST

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

BMYBMYBristol-Myers Squibb Company2026-10-23 11:30 EST

Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study

CGEMCullinan Therapeutics, Inc.2026-10-08 11:00 EST

Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia

Aprea Therapeutics

DNA Damage Response Oncology Aprea Therapeutics develops precision medicines that exploit vulnerabilities in cancer-cell DNA replication and repair. Its programs target biomarker-defined tumors while seeking to limit effects on healthy cells. APR-1051 APR-1051 is a selective oral WEE1 inhibitor in the Phase 1 ACESOT-1051 study for...

Recent company news

Stock data

Close
0.49 USD
Market cap
9.46M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States